Daniel P Nguyen1, Antoni Vilaseca1, Emily A Vertosick2, Renato B Corradi1, Karim A Touijer1,3, Nicole E Benfante1, Daniel D Sjoberg2, Paul Russo4,5. 1. Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 353 East 68th Street, New York, NY, 10065, USA. 2. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 307 East 63rd Street, New York, NY, 10065, USA. 3. Weill Cornell Medical College, New York, NY, USA. 4. Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 353 East 68th Street, New York, NY, 10065, USA. russop@mskcc.org. 5. Weill Cornell Medical College, New York, NY, USA. russop@mskcc.org.
Abstract
PURPOSE: To report survival outcomes of patients treated surgically for sarcomatoid-variant renal cell carcinomas (sRCC) and to assess whether the underlying histologic subtype is an independent predictor of outcome. METHODS: One hundred and fifty-one patients underwent surgery at a referral center between 1991 and 2014 and had sRCC in final pathology. Kaplan-Meier curves for metastasis-free survival and cancer-specific survival (CSS) were calculated, and the log-rank test assessed differences between clear cell sRCC and nonclear cell sRCC. Cox regression models were generated to test the prognostic value of histologic subtype. RESULTS: Of 151 patients, 120 (79 %) had clear cell sRCC and 31 (21 %) had nonclear cell sRCC. Ninety-eight (65 %) patients had M0/Mx disease at presentation. Among those M0/Mx patients, metastasis-free survival probabilities were 49 % at 2 years [95 % confidence interval (CI) 38-60] and 39 % at 5 years (95 % CI 28-50), while CSS probabilities were 50 % at 2 years (95 % CI 41-58) and 32 % at 5 years (95 % CI 24-41). There was no significant difference in metastasis-free survival between clear cell and nonclear cell sRCC (p = 0.8). However, patients with nonclear cell sRCC had significantly lower CSS than patients with clear cell sRCC (p = 0.035). In multivariable analyses, nonclear cell sRCC conferred a higher risk of cancer-specific death compared with clear cell sRCC (HR 2.30, 95 % CI 1.38-3.82, p = 0.001). CONCLUSIONS: In a cohort of patients treated surgically, the underlying histologic subtype of sRCC had an impact on CSS. These results present valuable information for individual counseling and patient selection in clinical trials.
PURPOSE: To report survival outcomes of patients treated surgically for sarcomatoid-variant renal cell carcinomas (sRCC) and to assess whether the underlying histologic subtype is an independent predictor of outcome. METHODS: One hundred and fifty-one patients underwent surgery at a referral center between 1991 and 2014 and had sRCC in final pathology. Kaplan-Meier curves for metastasis-free survival and cancer-specific survival (CSS) were calculated, and the log-rank test assessed differences between clear cell sRCC and nonclear cell sRCC. Cox regression models were generated to test the prognostic value of histologic subtype. RESULTS: Of 151 patients, 120 (79 %) had clear cell sRCC and 31 (21 %) had nonclear cell sRCC. Ninety-eight (65 %) patients had M0/Mx disease at presentation. Among those M0/Mx patients, metastasis-free survival probabilities were 49 % at 2 years [95 % confidence interval (CI) 38-60] and 39 % at 5 years (95 % CI 28-50), while CSS probabilities were 50 % at 2 years (95 % CI 41-58) and 32 % at 5 years (95 % CI 24-41). There was no significant difference in metastasis-free survival between clear cell and nonclear cell sRCC (p = 0.8). However, patients with nonclear cell sRCC had significantly lower CSS than patients with clear cell sRCC (p = 0.035). In multivariable analyses, nonclear cell sRCC conferred a higher risk of cancer-specific death compared with clear cell sRCC (HR 2.30, 95 % CI 1.38-3.82, p = 0.001). CONCLUSIONS: In a cohort of patients treated surgically, the underlying histologic subtype of sRCC had an impact on CSS. These results present valuable information for individual counseling and patient selection in clinical trials.
Authors: Hans J Hammers; Henk M Verheul; Brenda Salumbides; Rajni Sharma; Michelle Rudek; Janneke Jaspers; Preeti Shah; Leigh Ellis; Li Shen; Silvia Paesante; Karl Dykema; Kyle Furge; Bin T Teh; George Netto; Roberto Pili Journal: Mol Cancer Ther Date: 2010-05-25 Impact factor: 6.261
Authors: Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Siebels; Sylvie Negrier; Christine Chevreau; Ewa Solska; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Scott Freeman; Brian Schwartz; Minghua Shan; Ronit Simantov; Ronald M Bukowski Journal: N Engl J Med Date: 2007-01-11 Impact factor: 91.245
Authors: Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin Journal: N Engl J Med Date: 2007-01-11 Impact factor: 91.245
Authors: Sumanta K Pal; Jeremy O Jones; Courtney Carmichael; Junmi Saikia; Joanne Hsu; Xueli Liu; Robert A Figlin; Przemyslaw Twardowski; Clayton Lau Journal: Urol Oncol Date: 2012-05-17 Impact factor: 3.498
Authors: M de Peralta-Venturina; H Moch; M Amin; P Tamboli; S Hailemariam; M Mihatsch; J Javidan; H Stricker; J Y Ro; M B Amin Journal: Am J Surg Pathol Date: 2001-03 Impact factor: 6.394
Authors: G Kovacs; M Akhtar; B J Beckwith; P Bugert; C S Cooper; B Delahunt; J N Eble; S Fleming; B Ljungberg; L J Medeiros; H Moch; V E Reuter; E Ritz; G Roos; D Schmidt; J R Srigley; S Störkel; E van den Berg; B Zbar Journal: J Pathol Date: 1997-10 Impact factor: 7.996
Authors: Patrick E Teloken; R Houston Thompson; Satish K Tickoo; Angel Cronin; Caroline Savage; Victor E Reuter; Paul Russo Journal: J Urol Date: 2009-09-16 Impact factor: 7.450
Authors: Cedric Lebacle; Aydin Pooli; Thomas Bessede; Jacques Irani; Allan J Pantuck; Alexandra Drakaki Journal: World J Urol Date: 2018-06-01 Impact factor: 4.226